NeoGenomics

NeoGenomics

Yahoo Finance • 7 days ago

3 Healthcare Stocks with Questionable Fundamentals

3 Healthcare Stocks with Questionable Fundamentals From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial p... Full story

Yahoo Finance • 13 days ago

NeoGenomics anticipates $802M-$806M 2026 revenue as it targets mid-20% NGS growth and adjusts pharma expectations

Earnings Call Insights: NeoGenomics (NEO) Q2 2026 MANAGEMENT VIEW * "We're raising guidance because of these results as well as the underlying clinical strength we're seeing in the back half of this year." (CEO Anthony Zook) * "Tota... Full story

Yahoo Finance • 18 days ago

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

The First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) provides concentrated, high-conviction exposure to biotechnology firms, while the Vanguard Health Care ETF (NYSEMKT:VHT) offers a cheaper, diversified basket across the entir... Full story

Yahoo Finance • 20 days ago

Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

Key Points iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF carries a lower expense ratio... Full story

Yahoo Finance • 20 days ago

Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?

Investors choosing between the State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) and First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) must weigh XLV's broad healthcare diversification and low cost against FBT's conc... Full story

Yahoo Finance • 24 days ago

Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. NeoGenomics (NEO) drew fresh attention after announcing PTEN IHC C... Full story

Yahoo Finance • 29 days ago

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

Comparing First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) and iShares Biotechnology ETF (NASDAQ:IBB) reveals a choice between FBT's highly concentrated portfolio and IBB's broader, market-cap-weighted industry exposure. Both... Full story

Yahoo Finance • last month

NeoGenomics (NEO) Stock Trades Up, Here Is Why

NeoGenomics (NEO) Stock Trades Up, Here Is Why What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.4% in the afternoon session after the company announced the launch of the first FDA-approved... Full story

Yahoo Finance • last month

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP® FORT MYERS, Fla., July 09, 2026--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leadin... Full story

Yahoo Finance • 2 months ago

1 Unprofitable Stock for Long-Term Investors and 2 Facing Headwinds

1 Unprofitable Stock for Long-Term Investors and 2 Facing Headwinds Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Unprofitable compan... Full story

Yahoo Finance • 2 months ago

NeoGenomics launches $275M convertible notes offering due 2032

* NeoGenomics (NEO [https://seekingalpha.com/symbol/NEO]) announced [https://seekingalpha.com/pr/20552127-neogenomics-announces-proposed-offering-of-275-million-convertible-senior-notes] a private offering of $275M in convertible senior... Full story

Yahoo Finance • 3 months ago

Neo Partners with Greenland Mines to Advance Sarfartoq Rare Earth Project

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- Neo Performance Materials Inc. (“Neo” or the “Company”) (TSX: NEO; OTCQX: NOPMF) today announced that its wholly-owned subsidiary, Neo North Star Holdings Inc. (“NNSH”), together with the other s... Full story

Yahoo Finance • 3 months ago

Neo Performance Materials Q1 Earnings Call Highlights

Key Points Interested in Neo Performance Materials Inc.? Here are five stocks we like better. Neo Performance Materials raised its full-year 2026 adjusted EBITDA guidance to $100 million-$110 million from $75 million-$80 million after pos... Full story

Yahoo Finance • 3 months ago

3 Russell 2000 Stocks We’re Skeptical Of

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size... Full story

Yahoo Finance • 3 months ago

NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval

Earnings Call Insights: NeoGenomics (NEO) Q1 2026 MANAGEMENT VIEW * "Total revenue for Q1 was $186.7 million, representing 11% growth year-over-year, exceeding our guidance," said (CEO Anthony Zook), alongside "Adjusted EBITDA of $9 mi... Full story

Yahoo Finance • 4 months ago

How The Investment Story Is Shifting For Neo Performance Materials (TSX:NEO)

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. The latest update keeps Neo Performance Materials’ fair value estimate essentially steady at CA$28.10 per share, sitting just belo... Full story

Yahoo Finance • 4 months ago

2 Healthcare Stocks Worth Your Attention and 1 We Ignore

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for... Full story

Yahoo Finance • 4 months ago

Q4 Earnings Roundup: Quest (NYSE:DGX) And The Rest Of The Testing & Diagnostics Services Segment

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Quest (NYSE:DGX) and the rest of the testing & diagnostics services s... Full story

Yahoo Finance • 4 months ago

The West Is Building a Minerals Club — and China Isn't Invited

The West Is Building a Minerals Club — and China Isn't Invited - Moby THE GIST Washington and Brussels might disagree on many things, but securing and supplying critical minerals isn’t one of them. On that front, it’s them against China.... Full story

Yahoo Finance • 4 months ago

March 2026's Global Undervalued Small Caps With Insider Buying

As global markets navigate a volatile landscape marked by geopolitical tensions, inflation concerns, and fluctuating energy prices, small-cap stocks have experienced varied impacts. The S&P 600 Index for small-cap stocks reflects this unce... Full story